Key result
TKI-treated CML survivors are linked to a ~343% greater likelihood of poor general health versus controls.
Why the study?
Tyrosine kinase inhibitors have significantly reduced CML-related mortality, but their impact on the health status of long-term survivors remains unstudied.
Does tyrosine kinase inhibitor therapy impact the long-term health status of chronic myeloid leukemia survivors compared to non-cancer controls and BMT survivors?
Cohort (n=585)
Yes
Does tyrosine kinase inhibitor therapy impact the long-term health status of chronic myeloid leukemia survivors compared to non-cancer controls and BMT survivors?
Long-term TKI therapy in CML survivors is associated with significant health status impairments, highlighting the need for long-term monitoring and risk mitigation strategies.
Answers are grounded in this paper and cite their sources.
Long-term TKI-treated CML survivors warrant health status monitoring; leaves open whether interventions mitigate impairments.
Tyrosine kinase inhibitor (TKI) therapy has resulted in a significant reduction in chronic myeloid leukemia (CML)-related mortality. However, the impact of TKIs on the health status of long-term CML survivors remains unstudied. We examined the health status of 62 TKI-treated CML patients who did not receive blood or marrow transplantation (BMT) (CML_TKI; median follow-up: 12.5 y) compared with an unaffected population (303 non-CML controls), and CML patients treated with BMT but without TKI exposure (220 CML_BMT; median follow-up 19.4 y). Participants self-reported general health, functional status, activity limitations, and pre-frailty/frailty. Overall, 71.0% of CML_TKI participants had ≥1 adversely-affected domain vs. 42.6% of non-CML and 65.9% of CML_BMT participants. When compared with the non-CML controls, the CML_TKI cohort was more like to have poor general health (aOR = 4.43, 95%CI = 1.8–10.7), functional impairment (aOR=2.84, 95%CI = 1.4–6.0), and activity limitation (aOR=3.37, 95%CI = 1.7–6.7) and more likely to be frail/pre-frail (aOR=3.71, 95%CI = 1.7–8.1). The CML_TKI and CML_BMT cohorts were comparable with respect to poor general health (aOR = 0.95, 95%CI = 0.5–2.0), functional impairment (aOR = 1.59, 95%CI = 0.8–3.0), and pre-frailty/frailty (aOR = 1.92, 95%CI = 0.92–4.0), but the CML_TKI cohort was more likely to report activity limitation (aOR = 2.2, 95%CI = 1.1–4.5). These findings inform a need for long-term monitoring and development of risk mitigation strategies to improve the health status as a treatment goal in CML care.
No takes yet. Share an insight, caveat, or question.
Bhatia et al. (2026) conducted a cohort in Chronic myeloid leukemia (CML) (n=585). Tyrosine kinase inhibitor (TKI) therapy vs. Non-cancer controls and BMT-treated CML survivors was evaluated on Poor general health (vs non-CML controls) (aOR 4.43, 95% CI 1.8-10.7, p=0.001). Tyrosine kinase inhibitor-treated chronic myeloid leukemia survivors had a higher likelihood of reporting poor general health compared to non-cancer controls.
Synapse has enriched 10 related papers. Consider them for comparative context: